Introduction
Zepbound is one FDA-approved tirzepatide product sold in four presentations: a single-dose pen, a single-dose vial, a multi-dose vial, and a four-dose KwikPen. The drug and the dosing schedule are identical across them.
What changes is whether you draw the dose with a syringe or press a device, how many days each container lasts outside the refrigerator, which excipients are inside, which purchase channel carries it, and what Lilly charges per month.
Zepbound vial vs pen at a glance
The Zepbound label, revised in August 2026, lists the same six strengths, 2.5 through 15 mg, in every presentation. Single-dose pens and single-dose vials each hold 0.5 mL of one dose. The multi-dose vial and the single-patient-use KwikPen each hold 2.4 mL, enough for four weekly 0.6 mL doses. The choice among them is a prescriber decision that the label says should come with presentation-specific training.
The table lists what actually differs. Prices come from Lilly's savings page and, for per-dose vial prices, from trade coverage of Lilly's December 2025 announcement, because LillyDirect blocked our request on the access date.
| Feature | Single-dose pen | Single-dose vial | KwikPen (four doses) |
|---|---|---|---|
| Doses per container | One | One; cartons of one or four | Four weekly doses |
| How you inject | Fixed-dose device | Draw 0.5 mL with a new syringe and needle | Dial and inject; never share the pen |
| Preservatives | None listed | None listed | Benzyl alcohol, glycerin, phenol |
| Room-temperature limit | 21 days total at up to 86°F | 21 days total at up to 86°F | 30 days unopened; 30 days or four doses after first use |
| Self-pay channel | Savings card: as little as $25 with coverage, as low as $499 uncovered | LillyDirect: $299 for four 2.5 mg vials, higher doses by strength | LillyDirect: $299 at 2.5 mg, up to $699 at 10 to 15 mg |
| Medicare GLP-1 Bridge | Not covered | Not covered | Covered at $50 for eligible beneficiaries |
Same drug, same schedule, different container
Every presentation contains tirzepatide, a GIP and GLP-1 receptor agonist approved to reduce excess body weight in adults with obesity or overweight with a weight-related condition and to treat moderate to severe obstructive sleep apnea in adults with obesity. The label starts all patients at 2.5 mg once weekly for four weeks, then 5 mg, then optional 2.5 mg steps after at least four weeks each, to a 5, 10, or 15 mg maintenance dose and a 15 mg maximum. Nothing about that schedule changes with the container.
The formulation does change. Single-dose pens and vials contain tirzepatide with sodium chloride, sodium phosphate, and water. The multi-dose vial and KwikPen add benzyl alcohol, glycerin, and phenol as preservatives, which is why they can be opened and used over 30 days. Anyone with a known sensitivity to those excipients should raise it with the prescriber, since the label lists hypersensitivity to any excipient as a contraindication.
How vials and pens are used
A single-dose pen delivers its full 0.5 mL dose with a button press and is discarded. A single-dose vial holds the same 0.5 mL, but the patient draws it up with a syringe. The label tells patients using vials to use a new syringe and needle for every injection and a syringe able to measure a 0.5 mL or 0.6 mL dose accurately, and it tells prescribers to assess whether the patient can inject correctly with that presentation.
The KwikPen is dialed to the prescribed dose each week and holds four doses. The label warns that it must never be shared between patients, even with a new needle, and says it is not recommended for self-administration by people with visual impairment unless the prescriber decides they can use it properly. If a prescriber changes the presentation, the label calls for new training and the Instructions for Use for the new device.
Vial dosing depends on the syringe and the exact volume on the prescription. Telehealth Ledger does not publish syringe-unit conversions; use the Instructions for Use and the prescriber's written directions.
Storage days differ by presentation
All presentations are stored in the refrigerator at 36°F to 46°F, protected from light in the original carton, and must not be frozen. A single-dose pen or single-dose vial can spend up to a total of 21 days unrefrigerated at up to 86°F and is then discarded. An unopened KwikPen or multi-dose vial can be kept until its expiration date in the refrigerator but is thrown away after 30 days at room temperature.
Once a KwikPen or multi-dose vial is opened, it can stay in the refrigerator or at room temperature, but it is discarded after 30 days at room temperature, 30 days after first use, or after the fourth weekly dose, whichever comes first, even if medicine remains. For a traveler, the KwikPen's 30-day window is longer than the single-dose containers' 21 days, but the four-dose limit still applies.
Where each presentation is sold
All presentations are prescription products. The single-dose pen is the presentation most often filled through insurance at a retail pharmacy, and Lilly's savings card is written around it. The KwikPen and single-dose vials are the presentations Lilly sells to self-pay patients through LillyDirect, with home delivery or Walmart pharmacy pickup. Lilly's savings page says the prescriber may write for the single-dose pen, the single-dose vial, or the KwikPen.
Telehealth programs that offer Zepbound prescribe one of these Lilly presentations and route the prescription to a pharmacy or to LillyDirect. Compounded tirzepatide is a different, unapproved category and is not a Zepbound presentation, so a program listing should say which it sells.
What Zepbound vials and pens cost through Lilly
Lilly's savings page lists a self-pay starting price of $299 for a one-month prescription of the 2.5 mg KwikPen or four 2.5 mg single-dose vials, and states that the $299 figure applies to the KwikPen or vial, not the single-dose pen. Regular KwikPen prices are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10, 12.5, and 15 mg, with a $449 purchase offer on the 7.5 through 15 mg KwikPens that requires refills on schedule. Trade coverage of Lilly's December 1, 2025 announcement lists single-dose vials through LillyDirect at $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 through 15 mg; confirm the vial figures on LillyDirect, which our fetch could not reach.
The single-dose pen follows a different path. With commercial insurance that covers it, the Zepbound savings card can bring a one-month fill to as little as $25, capped at $100 of savings per month and $1,300 per year; without coverage the pen can be as low as $499 per month. The card excludes Medicare and other government programs and expires December 31, 2026. Eligible Medicare Part D beneficiaries pay $50 through the Medicare GLP-1 Bridge for the KwikPen only. The catalog module below shows telehealth program prices for Zepbound, which add clinician and membership fees to the medication.
Zepbound telehealth prices per month
Published telehealth program prices for Zepbound. Compare them with Lilly's own self-pay prices above to see what the program adds.
Pallas Health
Zepbound · Brand-name injection · medication included
Price source · checked 22 August 2026GobyMeds
Zepbound® · Weekly injection · medication included
Price source · checked 2 September 2026Sprout Health
Zepbound® · Weekly injection · medication included
Price source · checked 2 August 2026- Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What to ask a telehealth provider about vials and pens
Confirm the presentation and the money before the first fill.
- Which Zepbound presentation will be prescribed, and can it change if a pharmacy is out of stock?
- Is the prescription routed to LillyDirect, a retail pharmacy, or a partner pharmacy, and who charges for the medication?
- What does the program fee cover beyond Lilly's own price for the same dose?
- If a vial is prescribed, who provides syringes and the written measuring instructions?
- Will the program help with the savings card, insurance prior authorization, or the Medicare GLP-1 Bridge?
Common questions
- Is the Zepbound vial the same as the Zepbound pen?
- Yes, they contain the same FDA-approved tirzepatide at the same strengths. The vial requires a syringe, the pen is a fixed-dose device, and the KwikPen holds four doses with added preservatives.
- Why are Zepbound vials cheaper than pens?
- Lilly sells single-dose vials and the KwikPen to self-pay patients through LillyDirect at published prices starting at $299, while the single-dose pen is priced through insurance and the savings card. The vial trades a lower cash price for syringe handling.
- How long can Zepbound stay out of the refrigerator?
- A single-dose pen or vial can spend up to 21 days total at up to 86°F. An opened KwikPen or multi-dose vial is discarded after 30 days or four doses.
- Does Medicare cover Zepbound vials?
- The Medicare GLP-1 Bridge lists the Zepbound KwikPen but not the single-dose vial or single-dose pen. Part D plan coverage for other indications depends on the plan.
- Can I switch from Zepbound pens to vials?
- The label allows any presentation at the same dose, but it says a change in presentation requires new training and the Instructions for Use for the new device. The prescriber makes the change.
Pick the presentation by channel and handling, not by drug
The tirzepatide is the same in every Zepbound container. Vials and the KwikPen are Lilly's self-pay route with published prices; the single-dose pen is the insurance and savings-card route. Decide which channel you will use, confirm you can handle the presentation, and compare the full monthly cost.
Already on a zepbound plan? See which of 4 providers charge less than yours
Sources
- Zepbound prescribing information (DailyMed, revised 8/2026)Eli Lilly and Company via DailyMed, National Library of Medicine · Accessed 10 September 2026
Zepbound indications, single-dose pen, single-dose vial, multi-dose vial, and KwikPen strengths, dose escalation, storage limits, excipients, and administration instructions.
- Zepbound savings and self-pay pricingEli Lilly and Company · Accessed 10 September 2026
Self-pay starting price for the Zepbound KwikPen or four single-dose vials, regular KwikPen prices by dose, savings-card terms for the single-dose pen, and Medicare GLP-1 Bridge pricing.
- Lilly reduces price of Zepbound single-dose vials for self-pay patients (trade press; LillyDirect and the Lilly press release returned 403 and timed out on the access date)Pharmaceutical Executive · Accessed 10 September 2026
Per-dose self-pay prices for Zepbound single-dose vials through LillyDirect as announced December 1, 2025, and the Walmart pickup option.
- Medicare GLP-1 Bridge information for Part D plansCenters for Medicare & Medicaid Services · Accessed 10 September 2026
Covered formulations under the Medicare GLP-1 Bridge, the $50 copay, and the July 1, 2026 through December 31, 2027 window.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated September 1, 2026)U.S. Food and Drug Administration · Accessed 10 September 2026
Compounded drugs are not FDA-approved, adverse-event report counts for compounded semaglutide and tirzepatide as of May 31, 2026, salt-form and dosing-error concerns, and the 28-day multi-dose vial advice.
Refresh triggers
- Zepbound label revision affecting presentations, excipients, or storage
- Lilly self-pay, savings-card, or LillyDirect price change
- Medicare GLP-1 Bridge formulation or copay change
- Catalog price or provider-set change for Zepbound